Looking to add a few stocks to your portfolio that offer a healthy margin of safety? Here are a few names to consider.
Four new late-stage studies from Gilead Sciences demonstrate that it's once again raised the bar in treating hepatitis C. Can anything stop Gilead?
Companies are rolling out cardiovascular drugs in a bid to tap into a massive and growing market, but not every one of these companies belongs in investor portfolios.
As the first generation of the cholesterol-lowering drugs hits the market, investors should already be looking at the next-generation products.
Agenus Inc., Array BioPharma, and Idera Pharmaceuticals are expecting to release data from cancer drug trials in the coming year.
Advaxis and Agenus have been two of the best performing stocks of 2015. Can they continue to crush the broader markets or is it time to take profits?
One Foolish investor shines a bright light on his biotech stocks predictions for this year.
With Aegerion Pharmaceuticals down 500% from its all-time high, the current CEO's tenure is trying investors' patience.
AbbVie's management team had a lot to talk about on their last investor conference call. Here are my three takeaways you need to know when considering the stock for investment.
Advaxis, Ariad Pharmaceuticals, and Exelixis Inc. are three cancer fight companies that could generate out-sized gains for investors. A deeper look, however, suggests that only one company is a compelling buy right now.